⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2714000 | 0.98 | CA12 (0.47) | — | |
| SCHEMBL5700159 | 0.82 | — | — | |
| SCHEMBL2538708 | 0.78 | CA12 (0.53) | — | |
| SCHEMBL6640028 | 0.78 | CA12 (0.39) | — | |
| SCHEMBL18985748 | 0.77 | MKNK1 (0.36) | — | |
| SCHEMBL5700368 | 0.77 | CA12 (0.57) | — | |
| SCHEMBL29508302 | 0.77 | SLC6A4 (0.40) | — | |
| SCHEMBL17449617 | 0.77 | SLC6A4 (0.40) | — | |
| SCHEMBL12934590 | 0.76 | CYP1A2 (0.49) | — | |
| Hydrochloric Acid SCHEMBL27935953 | 0.76 | CA12 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930620-A | Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-114315705-B | URAT1 inhibitor, preparation method and application thereof | 杭州中美华东制药有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023107597-A2 | BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | disclosed |
| EP-2081572-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-29 | — | — | EP | disclosed |
| CN-101270120-A | Novel tricyclic derivatives, method for preparing same and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008003665-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-0735024-A1 | Antidepressant N-(Heteroarylaminoalkyl)-4-napthyl substituted piperidines and tetrahydroperidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| CN-1126473-A | Carbazole derivatives with 17,20-lyase-inhibiting activity | GLAXO GROUP LTD (GB) | 1996-07-10 | — | — | CN | disclosed |
| EP-0699196-A1 | CARBAZOLE DERIVATIVES WITH 17,20-LYASE-INHIBITING ACTIVITY | GLAXO GROUP LIMITED (GB) | 1996-03-06 | — | — | EP | disclosed |
| US-5472966-A | Antiserotonin agents; side effect reduction | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1994027989-A1 | CARBAZOLE DERIVATIVES WITH 17,20-LYASE-INHIBITING ACTIVITY | GLAXO GROUP LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |